- RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
For: Metastatic Non-small Cell Lung Cancer With MTAP DeletionUnited States · Argentina · Australia - RecruitingPHASE2
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
This study is for people with advanced non-small cell lung cancer that has a specific genetic change (homozygous MTAP deletion) and has progressed after previous treatments. It aims to see how safe and effective a new medicine called Navlimetostat (BMS-986504) is in these patients.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · China - Not yet recruitingPHASE2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This study is for people with advanced solid tumours that have a specific genetic change called an MTAP deletion. It's testing a new medicine, BMS-986504, alone and with other cancer treatments, to see how safe and effective they are.
For: Solid TumorsUnited States · Belgium · Canada - Not yet recruitingPHASE2
SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma
This study, called SELECTmeso, looks for new treatments for a type of cancer called mesothelioma. It checks your tumour for specific markers and then offers a treatment that might work best. The first part, SELECTmeso1, tests a drug called BMS-986504 for tumours with an MTAP deficiency.
For: MesotheliomaUnited Kingdom